NDAORALTABLET
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
AMVAZ (amlodipine maleate) by Dr. Reddy's Laboratories. Approved for essential hypertension. First approved in 2003.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMVAZ (amlodipine maleate) is an oral calcium channel blocker tablet approved in 2003 for treating essential hypertension. It works by blocking calcium influx into vascular smooth muscle cells, causing vasodilation and reduced blood pressure. Amlodipine is a first-line antihypertensive commonly used as monotherapy or in combination regimens.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a shrinking team and focus shift toward lifecycle management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
Started May 2018
36 enrolled
Hypertension
Career Relevance
Career opportunities on AMVAZ are limited and increasingly focused on defending market share against generics and managing brand transition rather than growth. Working on this asset offers experience in late-lifecycle product management, generic competition strategy, and portfolio rationalization—valuable skills but not a springboard for high-profile advancement within a specialty pharma environment.
Worked on AMVAZ at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.